Compare URBN & BLTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | URBN | BLTE |
|---|---|---|
| Founded | 1970 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.1B | 6.2B |
| IPO Year | 1995 | 2021 |
| Metric | URBN | BLTE |
|---|---|---|
| Price | $66.94 | $154.29 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 7 |
| Target Price | $86.91 | ★ $198.00 |
| AVG Volume (30 Days) | ★ 1.0M | 90.8K |
| Earning Date | 05-20-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 18.78 | N/A |
| EPS | ★ 5.06 | N/A |
| Revenue | ★ $6,165,376,000.00 | N/A |
| Revenue This Year | $10.67 | N/A |
| Revenue Next Year | $7.01 | $492.11 |
| P/E Ratio | $13.53 | ★ N/A |
| Revenue Growth | ★ 11.07 | N/A |
| 52 Week Low | $59.15 | $56.68 |
| 52 Week High | $84.35 | $200.00 |
| Indicator | URBN | BLTE |
|---|---|---|
| Relative Strength Index (RSI) | 44.04 | 44.66 |
| Support Level | $66.65 | $148.06 |
| Resistance Level | $68.67 | $161.28 |
| Average True Range (ATR) | 2.79 | 5.75 |
| MACD | -0.56 | -0.40 |
| Stochastic Oscillator | 21.92 | 36.94 |
Founded in 1970, Philadelphia-based Urban Outfitters is a multibrand apparel and home goods retailer that operates nearly 800 stores and e-commerce in the US, which accounts for about 87% of sales, as well as in other regions. Its retail nameplates are Urban Outfitters (22% of fiscal 2026 sales), Free People/Movement (26%), and Anthropologie (42%). Retail accounted for 86% of fiscal 2026 revenue, but Urban Outfitters also sells products through a wholesale operation, owns some restaurants, and operates a fast-growing clothing rental and resale business called Nuuly (9% of sales). Urban Outfitters primarily markets to young adults and offers products across apparel (66% of sales), home goods (16% of sales), accessories (13% of sales), and more.
Belite Bio Inc is a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases which have unmet medical need such as Geographic Atrophy (GA), the late atrophic (dry) form of age-related macular degeneration (AMD), and Stargardt disease type 1 (STGD1). In addition to its product candidate (tinlarebant) which is intended for the treatment of GA and STGD1, its drug development pipeline also includes a small molecule, orally administered compound, LBS-009, which is intended for the treatment of metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout.